Polidocanol - BTG

Drug Profile

Polidocanol - BTG

Alternative Names: PEM; Polidocanol Endovenous Microfoam; Polidocanol injectable foam; Varisolve PEM; Varisolve®; Varithena

Latest Information Update: 28 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BTG
  • Developer BTG; BTG International
  • Class Polyethylene glycols; Sclerosants; Vascular disorder therapies
  • Mechanism of Action Endothelial cell modulators; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Varicose veins

Highest Development Phases

  • Marketed Varicose veins

Most Recent Events

  • 25 Jul 2017 Launched for Varicose veins in Canada (IV)
  • 06 Jul 2016 The FDA approves a 30 day post-activation shelf life of polidocanol in USA
  • 06 Aug 2015 Registered for Varicose veins in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top